Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Acquired by Barclays PLC

Barclays PLC lifted its stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 51.2% in the third quarter, HoldingsChannel reports. The firm owned 33,306 shares of the company’s stock after acquiring an additional 11,273 shares during the quarter. Barclays PLC’s holdings in Acrivon Therapeutics were worth $233,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new stake in shares of Acrivon Therapeutics in the 2nd quarter valued at approximately $58,000. XTX Topco Ltd purchased a new stake in Acrivon Therapeutics in the second quarter valued at approximately $61,000. Rhumbline Advisers boosted its holdings in shares of Acrivon Therapeutics by 48.9% in the second quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock valued at $94,000 after acquiring an additional 5,320 shares during the period. Bank of New York Mellon Corp grew its position in shares of Acrivon Therapeutics by 50.1% during the second quarter. Bank of New York Mellon Corp now owns 36,632 shares of the company’s stock worth $212,000 after acquiring an additional 12,219 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after acquiring an additional 47,233 shares during the period. 71.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ACRV shares. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. BMO Capital Markets dropped their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. JMP Securities reissued a “market outperform” rating and issued a $17.00 target price on shares of Acrivon Therapeutics in a report on Monday, September 16th. Finally, LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Monday, September 16th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $23.67.

Acrivon Therapeutics Price Performance

Shares of NASDAQ ACRV opened at $6.62 on Monday. The firm’s 50-day moving average is $7.10 and its two-hundred day moving average is $7.46. The company has a market capitalization of $206.12 million, a PE ratio of -2.45 and a beta of 0.77. Acrivon Therapeutics, Inc. has a 12-month low of $3.19 and a 12-month high of $11.90.

Acrivon Therapeutics Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.